BourgaritA, CarcelainG, MartinezV, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS, 2006; 20:F1–F7.
2.
MüllerM, WandelS, ColebundersR, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: A systematic review and meta-analysis. Lancet Infect Dis, 2010; 10:251–261.
3.
MaraisS, MeintjesG, PepperDJ, et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis, 2013; 56:450–460.
4.
MeintjesG, WilkinsonRJ, MorroniC, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS, 2010; 24:2381–2390.
5.
RuslamiR, GaniemAR, DianS, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: An open-label, randomised controlled phase 2 trial. Lancet Infect Dis, 2013; 13:27–35.
6.
BrunelA-S, ReynesJ, TuaillonE, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. AIDS, 2012; 26:2110–2112.
7.
European Medical Agency. Thalidomide Celgene®(Previously Thalidomide Pharmion) -EMEA/H/C/000823 -PSU/0031 25/02/2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000823/WC500037050.pdf (Last accessed August18, 2014).
Van ToornR, RabieH, DramowskiA, SchoemanJF. Neurological manifestations of TB-IRIS: A report of 4 children. Eur J Paediatr Neurol, 2012; 16:676–682.
11.
RobertsMTM, MendelsonM, MeyerP, CarmichaelA, LeverAML. The use of thalidomide in the treatment of intracranial tuberculomas in adults: Two case reports. J Infect, 2003; 47:251–255.
